<h3>深度簡報：</h3>
<ul>
<li>PsiThera，前 Roivant Sciences 的子公司，週三宣佈在 A 輪融資中籌集了 4750 萬美元，以幫助開發其腫瘤壞死因子靶向藥物候選者的組合。</li>
<li>這家生物技術公司曾被稱為 Psivant Therapeutics，正在利用其專有的人工智能平台尋找能夠以口服形式提供生物藥物類似療效的新分子。</li>
<li>其早期投資者包括 Lightstone Ventures 和 Samsara BioCapital，這兩家公司共同主導了此次風險投資輪，以及 Roivant、YK Bioventures 和 Eurofarma Ventures。</li>
</ul>
<h3>深度洞察：</h3>
<p>靶向 TNF 的生物藥物改變了許多自身免疫疾病的治療方式。像 Humira 和 Enbrel 這樣的藥物有效對抗多種疾病，每年常常賺取數十億美元。但它們通常通過注射或輸液給藥，因此製造和管理更為複雜。</p>
<p>PsiThera 的目標是將這些生物藥物轉變為更便宜且更易服用的口服藥物。該公司依靠人工智能尋找新的方法來附着並阻斷 TNF，並相信可以通過預測和模擬蛋白質微小結構變化的方式，使小分子實現這一點，PsiThera 的創始人兼首席創新官 Woody Sherman 表示。</p>
<p><img src="https://imageproxy.pbkrs.com/https://imgproxy.divecdn.com/Y_CuiBWIuXP4iE2hZhny_GezgpUY5T6wYTpi5IU8gPo/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9Xb29keV9TaGVybWFuX2hlYWRzaG90XzIwMjQuanBn.webp?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://imgproxy.divecdn.com/Y_CuiBWIuXP4iE2hZhny_GezgpUY5T6wYTpi5IU8gPo/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9Xb29keV9TaGVybWFuX2hlYWRzaG90XzIwMjQuanBn.webp"/></p>
<p>Woody Sherman 是 PsiThera 的創始人兼首席創新官，曾被稱為 Psivant Therapeutics。</p>
<p>獲得 PsiThera 的許可</p>
<p>PsiThera 對生物藥物口服形式的可能性充滿熱情，週一 Kymera Therapeutics 的數據發佈使其股價飆升，宣佈一種口服蛋白降解劑似乎安全且對炎症靶點有效。</p>
<p>“在過去 10 年中，針對這些以前難以處理的靶點的口服療法的例子越來越多，” Sherman 説。</p>
<p>PsiThera 聲稱其人工智能平台可以縮短科學家尋找潛在分子到優化其用於臨牀前研究的時間。</p>
<p>與此同時，懷疑人工智能設計藥物的人對該技術能否找到高質量藥物持懷疑態度。少數進入臨牀測試的藥物，如 Recursion Pharmaceuticals 的神經血管藥物，並未顯示出顯著療效。</p>
<p>Sherman 和 PsiThera 首席執行官 Eric Shaff 意識到這些顧慮。然而，他們堅持認為現在仍處於早期階段，未來人工智能藥物發現的夢想可能會變為現實。</p>
<p><img src="https://imageproxy.pbkrs.com/https://imgproxy.divecdn.com/38nzXw1XO5GpCyHQGY0GPhKJIL3NVW0u9Gby6KWU1Rw/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9FcmljX0hlYWRzaG90LnBuZw==.webp?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://imgproxy.divecdn.com/38nzXw1XO5GpCyHQGY0GPhKJIL3NVW0u9Gby6KWU1Rw/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9FcmljX0hlYWRzaG90LnBuZw==.webp"/></p>
<p>Eric Shaff 是 PsiThera 的首席執行官。</p>
<p>獲得 PsiThera 的許可</p>
<p>“人工智能可能會改變遊戲規則，但人類在這個過程中扮演着至關重要的角色，” Shaff 説。</p>
<p>PsiThera 於 2022 年從 Roivant 分拆出來，後者推出了 Telavant 和 Dermavant 等公司，作為其 “中心 - 輻射” 生物技術創建模型的一部分。Shaff 表示，PsiThera 圍繞其藥物發現引擎建立，並在確定 TNF 作為首個靶點後進行外部推出。</p>
<p>該公司計劃在明年選擇其主導項目候選者。</p>
<p><em>更正：該故事的早期版本錯誤拼寫了 Eric Shaff 的姓氏，幷包含了 PsiThera 分拆的錯誤年份。</em></p>

ROIV

<p>PsiThera 是一家從 Roivant Sciences 分拆出來的公司，在 A 輪融資中籌集了 4750 萬美元，旨在開發針對腫瘤壞死因子的 AI 設計口服藥物，以治療免疫疾病。儘管對 AI 在藥物發現中的有效性存在懷疑，該公司仍希望利用其 AI 平台將生物製劑轉化為口服藥物。PsiThera 計劃在明年選擇其主要項目候選藥物</p>

<h3>Dive Brief:</h3>
<div class="lb-trans"><h3>深度簡報：</h3>
</div><ul>
<li>PsiThera, a former Roivant Sciences subsidiary, announced Wednesday it raised $47.5 million in a Series A round to help develop its portfolio of tumor necrosis factor-targeting drug candidates.</li>
<li>Once known as Psivant Therapeutics, the biotechnology company is using its proprietary artificial intelligence platform to find new molecules that can deliver biologic-like efficacy in an oral form.</li>
<li>Its early backers include Lightstone Ventures and Samsara BioCapital, which co-led the venture capital round, as well as Roivant, YK Bioventures, and Eurofarma Ventures.</li>
</ul>
<div class="lb-trans"><ul>
<li>PsiThera，前 Roivant Sciences 的子公司，週三宣佈在 A 輪融資中籌集了 4750 萬美元，以幫助開發其腫瘤壞死因子靶向藥物候選者的組合。</li>
<li>這家生物技術公司曾被稱為 Psivant Therapeutics，正在利用其專有的人工智能平台尋找能夠以口服形式提供生物藥物類似療效的新分子。</li>
<li>其早期投資者包括 Lightstone Ventures 和 Samsara BioCapital，這兩家公司共同主導了此次風險投資輪，以及 Roivant、YK Bioventures 和 Eurofarma Ventures。</li>
</ul>
</div><h3>Dive Insight:</h3>
<div class="lb-trans"><h3>深度洞察：</h3>
</div><p>Biologic medicines that target TNF, a protein involved in inflammation, changed the way many autoimmune conditions are treated. Drugs like Humira and Enbrel effectively combat a wide range of diseases and regularly earned billions of dollars annually. But they're also given via injections or infusions, and thus are more complicated to make and administer.</p>
<div class="lb-trans"><p>靶向 TNF 的生物藥物改變了許多自身免疫疾病的治療方式。像 Humira 和 Enbrel 這樣的藥物有效對抗多種疾病，每年常常賺取數十億美元。但它們通常通過注射或輸液給藥，因此製造和管理更為複雜。</p>
</div><p>PsiThera’s ambitions are to take those biologics and turn them into oral medications that are cheaper to produce and easier to take. The company is leaning on AI to find new ways to latch onto and block TNF, and believes it can make small molecules do so by predicting and simulating the minuscule ways that a protein changes its structure, also known as protein motion, said Woody Sherman, PsiThera’s founder and chief innovation officer.</p>
<div class="lb-trans"><p>PsiThera 的目標是將這些生物藥物轉變為更便宜且更易服用的口服藥物。該公司依靠人工智能尋找新的方法來附着並阻斷 TNF，並相信可以通過預測和模擬蛋白質微小結構變化的方式，使小分子實現這一點，PsiThera 的創始人兼首席創新官 Woody Sherman 表示。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://imgproxy.divecdn.com/Y_CuiBWIuXP4iE2hZhny_GezgpUY5T6wYTpi5IU8gPo/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9Xb29keV9TaGVybWFuX2hlYWRzaG90XzIwMjQuanBn.webp" alt="" original-src="https://imgproxy.divecdn.com/Y_CuiBWIuXP4iE2hZhny_GezgpUY5T6wYTpi5IU8gPo/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9Xb29keV9TaGVybWFuX2hlYWRzaG90XzIwMjQuanBn.webp"/></p>
<p>Woody Sherman is the founder and chief innovation officer of PsiThera, formerly known as Psivant Therapeutics.</p>
<div class="lb-trans"><p>Woody Sherman 是 PsiThera 的創始人兼首席創新官，曾被稱為 Psivant Therapeutics。</p>
</div><p>Permission granted by PsiThera</p>
<div class="lb-trans"><p>獲得 PsiThera 的許可</p>
</div><p>Adding to PsiThera’s enthusiasm for what’s possible for a biologic in a pill was Monday’s data readout from Kymera Therapeutics, whose shares skyrocketed on the announcement that an oral protein degrader appeared safe and worked on an inflammation target.</p>
<div class="lb-trans"><p>PsiThera 對生物藥物口服形式的可能性充滿熱情，週一 Kymera Therapeutics 的數據發佈使其股價飆升，宣佈一種口服蛋白降解劑似乎安全且對炎症靶點有效。</p>
</div><p>“There's been a growing number of examples over the course of the past 10 years of oral therapies for these previously intractable targets,” Sherman said.</p>
<div class="lb-trans"><p>“在過去 10 年中，針對這些以前難以處理的靶點的口服療法的例子越來越多，” Sherman 説。</p>
</div><p>PsiThera claims its AI platform can shrink the time scientists spend finding a potential molecule to optimizing it for preclinical studies.</p>
<div class="lb-trans"><p>PsiThera 聲稱其人工智能平台可以縮短科學家尋找潛在分子到優化其用於臨牀前研究的時間。</p>
</div><p>Skeptics of AI-designed drugs, meanwhile, have been unconvinced that the technology can find high-quality medicines. The few that have made it to clinical testing, such as Recursion Pharmaceuticals’ neurovascular drug, have not demonstrated meaningful efficacy.</p>
<div class="lb-trans"><p>與此同時，懷疑人工智能設計藥物的人對該技術能否找到高質量藥物持懷疑態度。少數進入臨牀測試的藥物，如 Recursion Pharmaceuticals 的神經血管藥物，並未顯示出顯著療效。</p>
</div><p>Sherman and PsiThera CEO Eric Shaff are aware of these reservations. Yet they maintain it’s still early days and that down the line, what may seem like a pipe dream for the future of AI drug discovery could become reality.</p>
<div class="lb-trans"><p>Sherman 和 PsiThera 首席執行官 Eric Shaff 意識到這些顧慮。然而，他們堅持認為現在仍處於早期階段，未來人工智能藥物發現的夢想可能會變為現實。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://imgproxy.divecdn.com/38nzXw1XO5GpCyHQGY0GPhKJIL3NVW0u9Gby6KWU1Rw/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9FcmljX0hlYWRzaG90LnBuZw==.webp" alt="" original-src="https://imgproxy.divecdn.com/38nzXw1XO5GpCyHQGY0GPhKJIL3NVW0u9Gby6KWU1Rw/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9FcmljX0hlYWRzaG90LnBuZw==.webp"/></p>
<p>Eric Shaff is the CEO of PsiThera</p>
<div class="lb-trans"><p>Eric Shaff 是 PsiThera 的首席執行官。</p>
</div><p>Permission granted by PsiThera</p>
<div class="lb-trans"><p>獲得 PsiThera 的許可</p>
</div><p>“AI may change the game, but humans have an essential role in the process,” Shaff said.</p>
<div class="lb-trans"><p>“人工智能可能會改變遊戲規則，但人類在這個過程中扮演着至關重要的角色，” Shaff 説。</p>
</div><p>PsiThera broke off in 2022 from Roivant, which launched companies like Telavant and Dermavant as part of its “hub-and-spoke” biotech creation model. PsiThera was built around its drug discovery engine, Shaff said, and launched externally once it identified TNF as its first target.</p>
<div class="lb-trans"><p>PsiThera 於 2022 年從 Roivant 分拆出來，後者推出了 Telavant 和 Dermavant 等公司，作為其 “中心 - 輻射” 生物技術創建模型的一部分。Shaff 表示，PsiThera 圍繞其藥物發現引擎建立，並在確定 TNF 作為首個靶點後進行外部推出。</p>
</div><p>The company plans to select its lead program candidate next year.</p>
<div class="lb-trans"><p>該公司計劃在明年選擇其主導項目候選者。</p>
</div><p><em>Correction: A previous version of this story misspelled Eric Shaff's last name, and included the incorrect year for PsiThera's spinout.</em></p>
<div class="lb-trans"><p><em>更正：該故事的早期版本錯誤拼寫了 Eric Shaff 的姓氏，幷包含了 PsiThera 分拆的錯誤年份。</em></p>
</div>

Roivant 的一家分拆公司正在押注於由人工智能設計的免疫疾病藥物